NasdaqGM · Biotechnology

Neurogene Inc (NGNE)

Stock, pipeline and biotech catalyst intelligence

Analyst view

Strong Buy+108.2%

$80.43 average target

$38.63+0.64 (+1.7%)Latest market snapshot · Yahoo Finance

Market cap$773.0M

Cash$225.4M

Quarterly burn$26.1M

Pipeline assets2

Short float17.9%

Latest coverage

News & Press Releases

External sources

Aug 11, 2026

Neurogene Reports Second Quarter 2026 Financial Results and Highlights Recent UpdatesBusiness Wire

Aug 11, 2026

Neurogene: Q2 Earnings SnapshotAssociated Press

Aug 4, 2026

Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business Wire

Continue with BioPharma ProUnlock 6 more recent stories and press releases.

Unlock Pro

Company profile

About Neurogene Inc

Neurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 that is packaged in an adeno-associated virus 9, which is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of Edinburgh, Virovek, Inc., Sigma-Aldrich Co. LLC., and Leland Stanford Junior University. The company was founded in 2018 and is headquartered in New York, New York.

Company profile supplied by Yahoo Finance. Catalyst dates can change and should be confirmed against the linked primary source.

Page updated Aug 21, 2026 · Yahoo quotes cached for one minute; reference data may be used when a live field is unavailable.